Literature DB >> 18587235

Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients.

Elísio Costa1, Susana Rocha, Petronila Rocha-Pereira, Henrique Nascimento, Elisabeth Castro, Vasco Miranda, Maria do Sameiro Faria, Alfredo Loureiro, Alexandre Quintanilha, Luís Belo, Alice Santos-Silva.   

Abstract

AIM: The aim of this work was to evaluate the neutrophil activation state in chronic kidney disease (CKD) patients under hemodialysis, and its linkage with resistance to recombinant human erythropoietin (rhEPO) therapy.
METHODS: We studied 63 CKD patients under hemodialysis and rhEPO treatment (32 responders and 31 non-responders to rhEPO therapy). In 20 of the CKD patients (10 responders and 10 non-responders to rhEPO therapy), blood samples were also collected immediately after dialysis. Twenty-six healthy volunteers were included in a control group. Hemoglobin levels, total and differential leukocyte counts, and circulating levels of C-reactive protein (CRP), elastase and lactoferrin were measured in all patients and controls.
RESULTS: Compared with controls, CKD patients presented with significantly higher CRP, neutrophil and elastase levels. When we compared the 2 groups of patients, we found that non-responders presented statistically significantly higher elastase plasma levels. A positive significant correlation was found between elastase levels and weekly rhEPO dose and CRP serum levels. After the hemodialysis procedure, a statistically significant rise in elastase, lactoferrin and, elastase/neutrophil and lactoferrin/neutrophil ratios were found.
CONCLUSIONS: Our data show that CKD patients under hemodialysis present higher elastase levels (particularly in non-responding patients), which could be related to the rise in neutrophils, and to be part of the enhanced inflammatory process found in these patients. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587235     DOI: 10.1159/000142147

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

1.  Evidence for anti-inflammatory effects of exercise in CKD.

Authors:  João L Viana; George C Kosmadakis; Emma L Watson; Alan Bevington; John Feehally; Nicolette C Bishop; Alice C Smith
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

2.  Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Liang Li; Chengyin Li; Yu Zhou; Qi Xu; Zilin Wang; Xiaoyun Zhu; Yuanming Ba
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

3.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

4.  Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: Molecular and biochemical studies.

Authors:  Samar K M Khalil; H A Amer; Adel M El Behairy; Mohamad Warda
Journal:  J Adv Res       Date:  2016-02-23       Impact factor: 10.479

Review 5.  Neutrophil Elastase Inhibitors and Chronic Kidney Disease.

Authors:  Elsa Bronze-da-Rocha; Alice Santos-Silva
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

6.  Influence of dry weight reduction on anemia in patients undergoing hemodialysis.

Authors:  Yinghui Deng; Hua Liu; Na Lin; Lina Ma; Wenjing Fu
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

7.  Co-occurrence of Protein Crotonylation and 2-Hydroxyisobutyrylation in the Proteome of End-Stage Renal Disease.

Authors:  Jingjing Dong; Yixi Li; Fengping Zheng; Wenbiao Chen; Shaoying Huang; Xianqing Zhou; Kang Wang; Wanxia Cai; HaiPing Liu; Lianghong Yin; Qiang Li; Donge Tang; Yong Dai
Journal:  ACS Omega       Date:  2021-06-10

8.  Polymorphisms of the ELANE Gene Promoter Region in End-Stage Chronic Kidney Disease Patients.

Authors:  Rafael Fernandes; Bruno Freitas; Vasco Miranda; Elísio Costa; Alice Santos-Silva; Elsa Bronze-da-Rocha
Journal:  Genes (Basel)       Date:  2016-04-29       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.